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SUMMARY 
• Primary Sjogren 's syndrome (SS) in humans is an 
autoimmune disease characterized by diffuse lymphoid cell 
infiltrates in the salivary and lacrimal glands, resulting in 
symptoms ofdiy mouth and dry eye due to insufficient secretion. 
The spectrum of presentation of the disease is broad, ranging 
from the organ-localized dysfunction of exocrine gland to 
systemic complications such as liver, kidney and lung invol 
vement. A significant proportion of the SS patients may de 
velop malignant lymphoproliferative disorders such as B cell 
lymphoma and macro globulinemia. Although it has been as 
sumed that a combination of immunologic, genetic, and en 
vironmental factors may play a key role on the development of 
autoimmune lesion in the salivary and lacrimal gland, little is 
known about the pathogenesis of primary SS. The hypofunc- 
tion of the salivary glands is associeted with lymphocytic 
infiltration, in which autoreactive T cells recognise unknown 
self-antigen and play a central role in the pathobiology ofSS. 
This disease is also characterized by systemic production of 
auto antibodies to ribonucleoprotein particles SS-A/Ro and 
SS-B/La, however, the specificity for this immunogenicity 
remains to be defined. The 120 kD a -fodrin is an important 
salivary gland autoantigen implicated in the development of 
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SS in both animal model and SS patients. This article will 
review recent observations of the immunological aspects of 
autoimmune sialadenitis as it occurs in SS patients, and in 
murine model for SS, and particularly emphasize on the role of 
salivary gland autoantigen during development of 
autoimmune lesions in SS. (Biomed Rev 1998; 9:131-141) 
INTRODUCTION 
• Sjogren's syndrome (SS) is a chronic autoimmune dis 
order affecting the salivary and lacrimal glands and leading to 
clinical symptoms of dryness of the mouth and eyes (sicca syn 
drome) (1-3). The syndrome is clinically subdivided into pri 
mary SS and secondary SS. In primary SS patients, a wide spe 
ctrum of extraglandular manifestations may occur, including 
vasculitis, thyroiditis, nephritis, pneumonitis, neuropathy, and 
lymphoproliferation, besides sicca syndrome (4-6). In second 
ary SS, the sicca symptoms are associated with an additional 
well-defined systemic autoimmune disorder, such as rheuma 
toid arthritis (RA), systemic lupus erythematosus (SLE), pro 
gressive systemic sclerosis (PSS), or primary biliary cirrhosis 
(PBC). The histopathological changes in the minor salivary 
gland biopsy are characterized by focal and/or diffuse lympho 
id cell infiltrates and parenchymal destruction. The majority of 
lymphoid cells in the salivary biopsy are CD4~ T cells with a small 
proportion of CDS" T cells (7). These T cells express the an- 
tybody antigen receptor and cell surface antigens associated 
with mature memory T cells. Recent studies suggest a preferen 
tial use of specific variable region segments of the antigen re 
ceptor (3 chain by salivary gland T cells (8). It can be suggested 
that an unknown organ-specific autoantigen targeted by 
  
  
autoreactive T cells may be present in the salivary glands. It was 
previously established and characterized an animal model for 
primary SS in NFS/sld mutant mice thymectomized 3 day after 
birth (3d-Tx), bearing autosomal recessive gene with sublin-
gual gland differentiation arrest (9,10). When the repertoire of T 
cell receptor (TCR) Vb genes transcribed and expressed within the 
inflammatory infiltrates was analysed in this animal model, a 
preferential utilization of TCR Vb gene was detected in these 
lesions from the onset of disease. Moreover, the antisali-vary 
duct autoantibodies were detected in sera from mice with 
autoimmune lesions. Recently, we succeeded in purifying a 120 
kD organ-specific autoantigen from the salivary gland tissues of 
this animal model. The sequence of the first 20 N-terminal 
residues was found to be identical to that of the human cyto- 
-skeletal protein a-fodrin(l 1). Furthermore, sera from patients 
with SS reacted positively with purified 120 kD antigen, and 
proliferative response of peripheral blood mononuclear cells 
from SS patients to the purified autoantigen was detected, but 
not from SLE or RA patients, and healthy controls. These results 
indicate that the anti-120 kD oc-fodrin immune response plays a 
critical role in the development of primary SS. 
IMMUNOREGULATION IN THE PATIENTS WITH 
SJOGREN'S SYNDROME 
• Although primary SS is characterized by autoimmune 
destruction of the salivary and lacrimal glands, a wide variety of 
extraglandular manifestation may occur. The spectrum of clini 
cal manifestation as autoimmune disorder found in SLE pati 
ents may also occur in SS patients (12). The tendency toward 
lymphoproliferation appears greater in SS than SLE, and the 
incidence of interstitial nephritis is higher in SS than SLE. 
Dryness of the skin has been attributed to a decrease in the sec 
retory capacity of the sebaceous glands, and the dryness of the 
skin and upper airways leads to particular clinical symptoms in 
the S S patients. Difficulty in swallowing is a frequent occurrence 
in primary SS patients due to decreased saliva production. Ab 
normal esophageal motility may also contribute to dysphagia 
in some primary SS patients. Clinical evidence of liver dysfunc 
tion is found to be 5% to 10% of primary SS patients (12). In a 
small proportion of primary SS patients, the presence of anti- 
mitochondrial antibodies indicates coexistence with PBC. It is 
uncommon for PBC patients to exhibit antibodies against SS-B 
antigen, and thus the PBC-associated sicca syndrome probably 
represents a form of secondary SS. Primary SS patients may ex 
hibit central and peripheral nervous system manifestations. It 
was reported that central nervous system abnormalities may 
occur in approximately 20% of primary SS patients. Peripheral 
neuropathies among primary SS include symmetric peripheral 
neuropathies andmononeuritis multiplex. The symmetric neu 
ropathies frequently present as sensory and motor components 
occur less frequently. The relative risk for primary SS patients 
of developing lymphoma has been estimated much higher than 
that of age-matched control subjects (13). The lymphomas are 
predominantly non-Hodgkin B cell (IgM-k) neoplasms that arise in 
the salivary gland and/or cervical lymph nodes. The distinc-
tionbetween malignant lymphomas and "pseudolymphoma" in 
SS patients is often quite difficult, even when recombinant DNA 
methods are clinically utilized (14,15). 
The most common autoantibodies in primary SS patients are 
antinuclear antibodies (ANA) and rheumatoid factor (12). The 
positive ANA is due to the presence of antibodies against SS- A/ 
Ro and SS-B/La antigens. Antibodies against SS-A/Ro react 
with a ribonucleoprotein (RNP) complex that contains a novel 
class of small RNA designated hYl-hY5 (h for human; Y for 
cytoplasmic) RNA, and it is now evident that such RNAs are 
also intranuclear components. The hY RNAs share many fea 
tures including sequence, and size (83-112 bp). However, the 
specificity for the immunogenicity of SS-A/Ro and SS-B/La 
remains unclear. It has been proposed that viral transcripts at 
tached to S S-B may lead to immune responses against the RNP 
complex in genetically predisposed individuals. A proposed, 
molecular mimicry hypothesis is that an immune response 
against any virus may cross-react with SS-B/La proteins. Al 
though functional studies have shown that salivary gland 
lymphocytes can produce autoantibodies in vitro (16,17), 
organ-specific autoantibodies have not yet been detected in 
primary SS patients.  
MURIME MODEL FOR SJOGREH'S 
SYNDROME 
• Several animal models for studying this autoimmune 
phenomenon in primary SS include autoimmune-prone mice 
which develop as an associated lesion (18-21), and spontane 
ously occurring age-related lesion in certain strain of mice (22, 
23). We have provided evidence that autoimmune sialade-nitis 
could be induced in non-autoimmune strain of 3d-Tx mice fol 
lowed by later immunization with salivary gland cells or tissue 
homogenate (24-26). A significantly higher incidence of autoim 
mune lesions in females was found, and the antisalivary duct 
autoantibodies were frequently detected in sera from mice with 
autoimmune lesions. The salivary gland autoimmune lesions 
first appeared in 4-week-old mice, and were aggravated with age 
until 20-week-old. Periductal inflammatory lesions quite resem 
bling human primary SS in the salivary and lacrimal gland 
developed exclusively in 3d-Tx NFS/sld mice. Extensive inflam 
matory lesions with parenchymal destruction were frequently 
observed in these mice. 
The inflammatory infiltration into the salivary and lacrimal 
glands consisted mainly of CD3~CD4~ T cells with lesserpropor-
tion of CD8~T cells and B220~B cells. Immunohistochemically, a 
large number of TCR VbS'cells was evident in all samples during 
the course of disease, and a small number of TCR Vb6~ T cells 
was also identified in the salivary and lacrimal gland. 
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Immunoreactive cells with mAbs to other TCRs examined were 
not clearly detected within these lesions. In control mice, sig 
nificant numbers of detectable T cells could not be observed in 
both the sali vary and lacrimal glands. FACS analysis of surface 
phenotype in the spleen cells showed a significant decrease of 
CD8~T cells in 3d-TXNFS/sld mice, compared with nontreated 
mice. Tissue infiltrating lymphocytes obtained from the in 
flamed subinandibular glands were analysed by flow cytometry. 
A predominance of CD4~Vb8~cells could be identified at each 
age, and a minor population of CD4~Vb6~ T cells was also iden 
tified. When the repertoire of TCR Vb genes transcribed within 
the inflammatory infiltrates was analysed by reverse-transcrib- 
edpolymerase-chain reaction (RT-PCR), a preferential utiliza 
tion of TCR Vb gene (Vb8 and Vb6 predominant) was detected 
in these lesions from the onset of disease. In experimental 
autoimmune encephalomyelitis, it has been shown that the 
repertoire of the autoreactive T cells is restricted. The Vb8.2 and 
Vb4 seg-ments were dominantly utilized by myelin basic 
protein-specific T cells in H-2umice, while Vb 17a was frequently 
observed in H-2S mice (27-29). Recent studies of human auto 
immune diseases have provided evidence for oligoclonality by 
the restriction fragment length polymorphism method. It was 
demonstrated that T cells of synovial fluid in patients with 
rheumatoid arthritis expressed TCR Vb7 transcripts (30) and 
brain biopsy specimens from multiple sclerosis preferentially 
expressed TCR Vb 10 gene (31).  
Immunohistochemical analysis was carried out to identify the 
particular cells responsible for production of various kinds of 
cytokines (TNF-oc, IL-2, IFN-y, IL-4, IL-6, and IL-10), and cell 
adhesion molecules (CAM) (ICAM-1, LF A-1, CD44, and Mel-14) in 
the salivary glands of 3d-TX NFS/sld mice. A variable proportion 
of cytokine-positive cells (TNF-oc, IL-2, IFN-y) was detected in the 
salivary glands from the onset of inflammatory lesions at 4 weeks 
of age. A smaller number of an ti-IL-10-positive cells were found 
within the inflammatory infiltrates after 4 weeks of age. Anti-IL-6-
positive mononuclear cells were detected in the periductal 
inflammatory infiltrates in the salivary glands at 12 weeks of age 
or more. In contrast, ICAM-1 -positive cells were observed mainly 
in vascular endothelial cells at age of 3 weeks before the onset 
of inflammatory infiltrates in the salivary glands. At 4 weeks 
of age or more, a considerable number of ICAM-1 -positive cells 
were seen in the inflammatory lesions in addition to the 
endothelial cells. LFA-1-, CD44-, and Mel-14-positive cells were 
constantly detected within the inflammatory lesions during the 
course of disease. 
We found the upregulation of cytokine genes (Fig. 1) and CAM 
genes (ICAM-1, LF A-1, CD44, Mel-14) in the salivary glands by 
RT-PCR, which were supported by immunohistochemistry.The 
expression of IL-4 mRNA was not detected throughout the 
course of autoimmune disease in this animal model. FACS 
analysis demonstrated that a significant proportion of splenic 
CD4~ 
T cells express activation markers (CD44, LFA-1, Mel-141ow, 
CD45RBlow) at a high level, and an increase in expression of 
B220~ B cells bearing I-Aq class-II molecules. Therefore, it is 
possible that the organ-specific autoantigen is targeted by 
clonally expanded autoreactive CD4~T cells with Th 1 cytokine 
profile. In this animal model, autoimmune lesions develop 
exclusively in the salivary and lacrimal glands, indicating that the 
organ-specific autoreactive CD4T cell clone generated in the 
periphery before 3 day after birth play an essential role for the 
development of salivary and lacrimal gland autoimmunity. It is 
now considered that the autoreactive CD4T cells are controlled 
by CD4~T cells with suppressor or regulatory activity that can 
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Figure 1. Expressions of cytokine, TCR Cb, and fi-
actin mRNA in the tissue-infiltrating mononuclear 
cells into the salivary glands of 3dTx NFS/sld mice 





derstand the pathogenic mechanism leading to spontaneous 
autoimmune lesions in the salivary glands, we attempted to clarify 
whether CD4+T cells are activated after the 3 d-TX treatment in the 
periphery. It is important to know whether autoreactive T cells 
generated in the periphery are spontaneously activated or not. 
We found that significant proportions of splenic CD4+T cells 
from this mouse model expressed activation markers CD44, LFA-1, 
Mel-141ow, CD45RBlow at a high level. Many previous studies 
demonstrated that mature T cell populations include cells 
thatrecognize and respond to self-antigens, but these cells are 
normally harmless because they are not activated (3 3). It has been 
recently reported that only very small fractions of the large 
numbers of potential disease-causing T cells are spontaneously 
activated in TCR transgenic model (34,35). We suggest that 
local upregulation of Thl cytokinesandCAM may be involved in 
the cascade of events that initiate and accelerate organ-specific 
autoimmunity in the salivary glands. Autoreactive T cells in this 
animal model may be triggered by an in situ activation through 
unknown autoantigen stimuli in the salivary glands. 
Moreover, we confirmed these experimental evidences using 
another SS model (36). The non-obese diabetic (NOD) mouse 
develops spontaneous autoimmune sialadenitis besides a well-
characterized T cell-mediated autoimmune insulitis (37-40). Im-
munohistochemical analysis showed that the vast majority of 
inflammatory infiltrates in the salivary glands were CD4+Vb8" 
and CD4J'Vb6+ T cells, whereas CD8+T cells and B220+B cells were 
fewer in number. We used RT-PCR to analyse the repertoire of TCR 
Vb chain genes expressed in the isolated infiltrating cells from 
affected salivary glands. Predominant expression of the Vb8 
and Vb6 gene segment was detected in the infiltrating cells in the 
salivary glands very early, and age-related diversity of TCR 
Vb gene usage was observed. Single-strand conformation 
polymorphism (SSCP) analysis demonstrated a strikingly 
symmetrical distribution of expanded clones in the PCR 
products of the Vb8 and Vb6 gene in the cells infiltrating the 
salivary glands. Nucleotide sequencing of amplified TCR Vb 
cDNA revealed that T-cellclonotypes had a high incidence of 
identical clones, indicating thatthe immune response 
inNODsialadenitis is driven by common stimuli. From these 
findings, we concluded that in autoimmune sialadenitis of murine 
models, there might be a restricted usage of TCR Vb elements in 
the early stage of the autoimmune lesion to recognize unknown 
self-antigen. Our recent study has demonstrated that a cleavage 
product of 120 kD a-fodrin may be an important salivary gland 
autoantigen in the development of SS, and thus anti-a-fodrin 
antibodies have been frequently detected in sera from patients 
with primary SS. 
IDENTIFICATION OF SALIVARY GLAND 
AUTOANTIGEN AND ITS CLINICAL APPLICATION 
• The TCR Vb gene is preferentially used in the salivary 
gland autoimmune lesions from the onset of disease, and high 
concentrations of anti-salivary duct autoantibodies of IgG type 
were detected in sera from these mice (Fig. 2A). To identify an 
organ-specific antigen, the salivary gland autoantigen reactive 
with affinity purified IgG from sera of 3d-TxNFS/sld mice was 
detected by Western blotting; no reactivity was detected in 
tissue homogenates from the lung, liver, heart, kidney, 
pancreas, spleen, and brain. Moreover, no reactivity was 
expressed in tissue homogenates from the salivary glands in other 
mouse strains such as BALB/c and C3H/He. To purify the 
salivary gland autoantigen, the tissue homogenates of these mice 
were subjected to fast protein liquid chromatography (FPLC) 
on Superose 12 HR. The fraction containing autoantigen 
activity was further purified by ion exchange high performance 
liquid chromatography (HPLC) on DEAE Cosmogel. 
Autoantigen activity was recovered in fractions 27 and 28. 
Western blotting of these fractions gave a major band of 120 kD 
(Fig. 2B). To identify the 120 kD salivary gland protein, we 
electroblotted the band onto an Immobilon membrane and 
directly sequenced it with an Applied Biosystems 477A 
Protein Sequencer. The bands were shown to possess a single 
N-terminal sequence. This sequence was identical to the N-
terminal sequence of human a-
fodrin:RQKLEDSYRFQFFQRDAEEL(41-43). 
Proliferative T cell responses of spleen cells from 3d-TxNFS/sld 
mice to the identified 120 kD antigen developed spontaneously at 
4 weeks of age, consistent with the onset of the autoimmune 
lesions in the salivary gland. This response increased at 8 and 12 
weeks of age, then declined by week 16. In contrast, no response 
was detected with control antigens (fraction 40, lysozy-me, and 
a-amylase). The spontaneous development of a pro-liferative T 
cell response to the 120 kD antigen is consistent with endogenous 
priming. We tested the 120 kD antigen-reactive T cells for 
additional properties to confirm the specific T cell responses. 
Splenic T cells from 8-week-old3d-TxNFS/sldmice challenged 
with the 120 kD antigen produced IL-2 and IFN-y. Thus, a 
potentially pathogenic Thl-type T cell population may be 
spontaneously primed to the 120 kD salivary gland autoantigen 
early in the development of autoimmune lesions in the salivary 
glands of this mouse model. To examine the organ-specificity 
ofthe 120 kD a-fodrin, we investigated various tissue 
homogenates in 3d-Tx NFS/sld mice immunoblotted with a 
commercially available monoclonal antibody to a-fodrin. More of 
a-fodrin was detected in the salivary gland homogenate than in 
homogenates from other organs. These data suggest that the 
salivary gland expression of a-fodrin may be an initial response 
in the development of autoimmune lesions in the salivary 
glands. Polyclonal rabbit antibodies to a synthesized a-fodrin 
N-terminal peptide reacted with the 120 kD salivary gland 
antigen upon Western blotting. Epithelial duct cells were 
intensely stained for antibodies against synthetic a-fodrin peptide 
in the salivary glands with autoimmune lesions, but not in non-
thymectomized and normal control mice. 
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Figure 2. Detection of anti-salivary gland autoantibodies in the salivary glands by the indirect imniunofhiorescence antibody 
technique (A). HPLC fractionation on DEAE Cosmogel (B). The purified 120 kD antigen was detected by Western blotting in 




To test the specificity of the a-fodrin as the salivary gland 
autoantigen, we constructed a recombinant a-fodrin fusion 
protein using the glutathione S-transferase (GST) fusion system 
in Escherichia coli. JS-1 cDNA, encoding the N-terminal 
portion, was constructed by inserting cDNA (1-1784bp) into the 
EcoRI site of pGEX-2T. Purified recombinant JS-1 protein was 
determined by examining its reactivity with sera from 3d-TxNFS/ sld 
mice. The reactivity with sera containing antibodies to 120 kDa-
fodrin was confirmed by Western blotting. Spleen cells from 
3d-Tx mice proliferated to the recombinant JS-1 fusion protein. 
It was also investigated of whether the intra-venous injection 
of the recombinant a-fodrin protein protects animals against the 
development of autoimmune lesions. The treatment with 
intravenous injection of recombinant JS-1 protein (25 mg) 
inhibited the development of autoimmune conditions including 
lymphocytic infiltration and autoantibody production to the 
whole 120 kD molecules. To confirm the disease specificity of 
a-fodrin and the recombinant JS-1 protein as an autoantigen in 
primary SS, we investigated sera from other autoimmune diseases, 
including secondary SS, such as SLE, RA, and from normal 
healthy individuals, in addition to patients with primary SS. As a 
result, 41 sera among 43 patients with primary SS were positive for 
both the purified 120 kD antigen and the recombinant JS-1 
protein on Western blots (95.35%), whereas sera from all patients 
with SLE and RA and from normal healthy individuals were 
negative (Fig. 3). Moreover, a-fodrin was detected in tissue 
homogenates of lip biopsies from patients with primary SS, but 
not in control materials. These data support the hypothesis that a-
fodrin may be expressed in the salivary glands of both the 
mouse model of SS and the patients with SS. Furthermore, we 
detected proliferative T cell response to the purified 120 kD 
antigen using peripheral blood mononuclear cells from 
patients with primary SS. These data indicate that a-fodrin is a 
key target autoantigen in the induction of primary SS in 
humans. 
Fodrin is a major component of the cortical cytoskeleton of 
most eukaryotic cells, and it forms heterodimers aligned in a side 
to side manner composed of one a (240 kD) and one (3 (235 kD) 
subunit (41,42). a-fodrin is an actin-binding protein that is found 
at the periphery of chromaffin cells and may be involved in 
secretion (44-46). The stimulation of secretion in parotid 
acinar cells is associated with dramatic rearrangements of the 
subplasmalemmal cytoskeleton, particularly of a-fodrin (47). 
Fodrin possesses binding sites for various proteins including 
actin (46), calmodulin (48-51), and CD45 (52,53). Proteolytic 
cleavage of a-fodrin resulting from the activation of a neutral 
calcium-activated protease (calpain) could be responsible for 
these conformational changes (54). The fodrin a-subunit is 
cleaved in association with apoptosis, and the 120 kD fragment is 
a breakdown product of the fodrin a-subunit (55). The pro-
teolysis of fodrin during apoptosis may be a consequence of 
unknown protease activation, a-fodrin is recently found to be 
cleaved by the calcium-activated protease calpain in apoptotic T 
cells, and by calpain and caspases in anti-Fas-stimulated 
Jurkat cells and/or neuronal apoptosis (56). We therefore speculate 
that an increase in the activity of apoptotic proteases is 
involved in the progression of a-fodrin proteolysis during 
development of SS. Fodrin cleavage during apoptosis may ha--ve 
implications for the membrane blebbing seen during this 
process. When human T cell leukemia CEM cells were induced to 
undergo apoptosis by exposure to either anti-Fas Ab, C2-
ceramide, or staurosporin, the 240 kD a-fodrin was cleaved to a 
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containing fewer apoptotic cells, a larger fragment of 150 kD was 
observed (57). It is plausible that the 120 kD fragment is a 
breakdown product ofthe 150 kD a-fodrin cleavage (55,56). 
Analysis of proteolytic events associated with apoptosis to 
define the mechanisms leading to protease activation, and to 
identify key substrates whose cleavage might be linked to the 
profound changes in cellular architecture. There is increasing 
evidence that calpain is overactivated in autoimmune 
conditions and subsequent tissue destruction (58,59). 
Altogether, an increase in the activity of cysteine proteases 
through unknown mechanisms is probably involved in the 
progression of a-fodrin proteolysis during the initial stages in 
the development of primary SS. 
Autoantibodies are produced to the pyruvate dehydrogenase 
complex in PBC (60), thyroid peroxidase in Hashimoto's disease 
(61). glutamic acid decarboxylase in insulin-dependent diabetes 
(39,40), FT/IC-ATPase in pernicious anaemia (62), and RNA 
polymerase 1 (RNA pol I) in SLE and RA (63). In SS. 
autoantibodies are generated to RNP particles SS-A/Ro and 
SS-B/La. Among them, disease-specific autoantibodies have 
only rarely been described. Despite the recent acquisition of 
extensive information relating to the mechanisms of self-
tolerance, understanding of those leading to pathogenic auto 
immunity remains obscure. Autoantigens can stimulate primary T 
cellproliferative responses, which suggests that many autoreac-
tive T cells escape deletion and remain in an unresponsive state. 
The identification ofthe salivary gland 120 kD a-fodrin is of 
relevance in elucidating the crucial role of this autoantigen in 
the development of primary SS. 
IMMUNE RESPONSE AGAINST THE SALIVARY GLAND 
AUTOAMTIGEM 
• A correlation between the cellular manifestations and 
the production of autoantibodies during the course of autoim 
mune diseases has not yet been analysed. To elucidate the 
mechanisms ofthe anti-120 kD a-fodrin immune response in 
vivo, we analysed NOD mice as a model for SS during develop 
ment of autoimmune sialadenitis. We found a specific autoan- 
tibody production against a-fodrin, and its production corre 
lates closely with autoimmune sialadenitis. Protein immuno- 
blotting revealed that sera from NOD mice were positive for 
a-fodrin from the onset of disease at 10 weeks of age. Auto-   
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Figure 3. Western blot analysis of the 120 kD a-fodrin and recombinant fusion protein, JS-l, ^vith human sera from autoimmune 
diseases. Sera from patients with primary SS were positive for the 120 kD antigen, whereas those from all patients with SLE, 
RA, and normal healthy donorswere negative. Representative imimmoblotting profiles wereselecledfrom each group. Western 
blots ofthe purified 120 kD a-fodrin (A). Western blots of the recombinant fusion protein, JS-l (70 kD protein is an artifact 
band q/'Escherichia coli degradation) (B). From Ref 11. 
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antibody production con-elated closely with inflammatory 
infiltration in the salivary glands in NOD mice until 30 weeks of 
age. To examine the organ specificity of a-fodrin, we immuno-
blotted salivary gland homogenates with polyclonal antibodies to 
synthetic a-fodrin of the purified 120 kD antigen. More a-
fodrin was detected in the salivary gland homogenates from 
NOD andNFS/sld mice, but not from control BALB/c mice. The 
content of IL-2, IL-4 and IFN-yby ELIS A in culture supematants of 
spleen cells from 8-, 12-, and 16-week-old NOD mice 48 h after 
challenge with a-fodrin antigen was determined. We detected a 
significant level of IL-2, IFN-y, but not of IL-4 produced in 
culture supematants measured by ELISA. Proliferative T cell 
response to a-fodrin antigen develops spontaneously in NOD 
mice in a defined chronological order. Antigen-stimulated blas-
togenesis was detected in spleen cells from 10- to 16- week-old 
female NOD mice, as the same level of NFS/sld mouse model. A 
specific T cell response of splenocytes against a-fodrin auto-
antigen was observed in NOD mice from the early onset of 
autoimmune sialadenitis, and in vitro cytokine production by 
splenic T cells such as IL-2 and IFN-y, but not IL-4, was detected by 
ELISA. A variable proportion of cytokine-positive cells 
(TNF-a, IL-2, IFN-y, and IL-10) was detected in the salivary 
glands at 10 weeks of age, and their numbers increased with age 
until 30 weeks. IL-6-positi ve mononuclear cells were found in 
the affected glands from 16 weeks of age. No IL-4-positive cells 
were detected in any of the inflammatory lesions. Figure 4 shows 
the representative immunohistochemical features of the 
infiltrating cells positive for cytokmes in the salivary glands from 
a 16-week-old NOD mouse. We detected significant levels of 
cytokine mRN A expression of IL-1 (3, TNF-a, IL-10, and IL-12 (p40) 
in the mononuclear cells isolated from salivary glands of NOD 
mice at 8 weeks of age, before the development of inflammatory 
lesions (Fig. 5). Because Cb mRN A was clearly detected at 8 
weeks of age, very early T-cell infiltrates may develop in the 
salivary glands of NOD mice before the onset of the histological 
changes. Inparticular, a significantly higher level of IL-12 (p40) 
expression was observed during early stage of disease. We 
found the upregulation of local cytokine genes including Thl 
cell type (IL-1 (3, TNF-a, IL-2, IFN-y, IL-6, IL-10, and IL-12 (p40) in 
the tissue-infiltrating cells at various ages determined by RT-
PCR and Southern blot analysis, but expression of IL-4 
mRNA was not detected at any age. The mRN A11'""' expression 
  
  
Figure 4. Immunoperoxidase staining of infiltrating mononuclear cells in the salivarv gland of a 16-week-old female NOD 
mouse. A variable number of cells were positive for IL-2 (A), IFN-y (B). IL-6 (C), and IL-10 (D).  x 240. 
 
 







was associated with detectable mRNA"""2 and mRNA"'N"Y 
expressions. This pattern of cytokine mRNA expression in the 
salivary glands of NOD mice differs from those reported in 
organ-specific autoimmune diseases (64). We have 
demonstrated that the autoreactive CD4"T cells in the salivary 
glands composed mainly of Thl cells during the course of 
autoimmune lesions. Likewise, these cells exhibit cytokine niRNA 
expression including 1L-2, IFN-y, and IL-10 (65,66). In the BB 
rat, it was suggested that IFN-y and IL-12 may play a major role in 
the expression of insulitis and thyroiditis (67). Also, IL-10 and 
IL-12 play a critical role in the initial phase of development of 
autoimmune sialdenitis in MRL/lpr mice (68). Although IL-10 is 
















of the immune responses, recent reports have demonstrated 
that IL-10 accelerates the development of autoimmune lesions in 
NOD insulitis and NZB/WF1 mice (69,70), and that Th 1 
development of naive CD4~ T cells depends on the coordinate 
action on IL-12 and IFN-y (71). Since IL-12 has a striking effect in 
increasing production of IFN-y by T cells (72), local IL-12 
production may play an important role in the development of 
Th 1 -type autoimmune sialadenitis in NOD mice through IFN-y 
production. It is possible that in spontaneous autoimmune 
sialadenitis in NOD mice, there may be a specific anti-a-fodrin 
immune responses on the development of autoimmune lesions, 
and that the autoreactive CD4~T cells possess an unregulated 
Thl -cytokine profile besides IL-10 and IL-12. 
CONCLUSION 
• The identification of the salivary gland autoantigen, 
120 kD a-fodrin, is of relevance in elucidating its increasingly 
crucial role in the development of primary SS. Additional infor 
mation about fine epitope mapping in both T and B cells, the 
nature of the etiologic autopeptide in immune recognition, and 
the function of autoreactive T cells in tissue destruction will 
provide new insights into the appropriate diagnosis and the 
therapy for autoimmune diseases in the salivary glands. 
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